Avacta Group Plc (LON:AVCT)‘s stock had its “corporate” rating reissued by equities research analysts at FinnCap in a note issued to investors on Tuesday. They presently have a GBX 200 ($2.48) target price on the stock. FinnCap’s price objective would indicate a potential upside of 125.99% from the company’s previous close.

Separately, Numis Securities Ltd reissued a “buy” rating on shares of Avacta Group Plc in a research note on Monday, August 1st.

Shares of Avacta Group Plc (LON:AVCT) opened at 87.05 on Tuesday. Avacta Group Plc has a 52-week low of GBX 83.02 and a 52-week high of GBX 134.50. The stock’s 50 day moving average price is GBX 89.99 and its 200 day moving average price is GBX 95.94. The company’s market capitalization is GBX 59.44 million.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/29/avacta-group-plc-avct-stock-rating-reaffirmed-by-finncap-2.html.

In related news, insider Mike Owen bought 7,763 shares of the company’s stock in a transaction on Friday, October 21st. The stock was bought at an average cost of GBX 90 ($1.12) per share, for a total transaction of £6,986.70 ($8,667.29).

Avacta Group Plc Company Profile

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development.

Receive News & Stock Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related stocks with our FREE daily email newsletter.